A5046279416- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Viral-associated cancers and disorders
- Cancer Immunotherapy and Biomarkers
- Monoclonal and Polyclonal Antibodies Research
- Immune Cell Function and Interaction
- T-cell and Retrovirus Studies
- CNS Lymphoma Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Cutaneous lymphoproliferative disorders research
- Lung Cancer Treatments and Mutations
- Glioma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Lung Cancer Research Studies
- Radiomics and Machine Learning in Medical Imaging
- Gastric Cancer Management and Outcomes
- Brain Metastases and Treatment
- Ovarian cancer diagnosis and treatment
- Integrated Circuits and Semiconductor Failure Analysis
- Histone Deacetylase Inhibitors Research
- HER2/EGFR in Cancer Research
- Nanoplatforms for cancer theranostics
- Cancer, Hypoxia, and Metabolism
- Protein Degradation and Inhibitors
Zhejiang Cancer Hospital
2016-2025
Hunan Cancer Hospital
2025
Central South University
2017-2025
First People’s Hospital of Zunyi
2025
Chongqing University
2024-2025
Nanchang University
2024
University of Chinese Academy of Sciences
2020-2024
Cancer Hospital of Chinese Academy of Medical Sciences
2020-2024
Hangzhou Cancer Hospital
2023-2024
Chinese Academy of Sciences
2021-2024
Abstract Purpose: Mantle-cell lymphoma (MCL) is an incurable mature B-cell neoplasm with high initial response rates followed almost invariably by relapse. Prognosis for patients following relapse poor, and treatment choices are limited. We evaluated the efficacy safety of zanubrutinib, investigational selective Bruton's tyrosine kinase (BTK) inhibitor. Patients Methods: relapsed/refractory MCL were enrolled in this ongoing phase II, single-arm, open-label study, treated oral zanubrutinib...
Bruton tyrosine kinase (BTK) inhibitor is an established treatment for relapsed/refractory (R/R) mantle cell lymphoma (MCL). Zanubrutinib, a highly selective BTK inhibitor, approved patients with MCL who have received ≥1 prior therapy. We report the long-term safety and efficacy results from multicenter, open-label, phase 2 registration trial of zanubrutinib. Patients (n = 86) oral zanubrutinib 160 mg twice daily. The primary endpoint was overall response rate (ORR), assessed per Lugano...
Abstract Prognosis is poor for patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) after failure of or who are ineligible autologous stem cell transplant. We evaluated the efficacy and safety tislelizumab, an investigational anti-PD-1 monoclonal antibody, in phase 2, single-arm study Chinese R/R cHL. The primary endpoint was overall response rate as assessed by independent review committee, according to Lugano 2014 Classification. Seventy were enrolled received at least...
Abstract Background Despite numerous chimeric antigen receptor T‐cell (CAR‐T) trials conducted in China, no CAR‐T has been registered the country. Furthermore, China law and regulations restrict export of patient material for manufacture abroad. Relma‐cel (JWCAR029), an anti‐CD19 product produced with a commercial‐ready process was evaluated first prospective, single‐arm, multicenter, pivotal study therapy under Chinese IND to support NMPA‐accepted BLA submission relapsed/refractory (r/r)...
Relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL) is a rare and aggressive type of non-Hodgkin with limited treatment options. This phase II study evaluated the efficacy safety sugemalimab, an anti-PD-L1 monoclonal antibody, in R/R ENKTL.Eligible patients received sugemalimab 1,200 mg intravenously once every 3 weeks for up to 24 months until progression, death, withdrawal. The primary end point was objective response rate (ORR) assessed by independent radiologic...
Abstract Introduction The prognosis of relapsed or refractory mature T‐ and natural killer (NK)‐cell lymphoma remains dismal. Novel agents are urgently needed to improve the outcomes for this population. Methods In phase 2, multicenter, open‐label, single‐arm study (NCT03776279), authors report efficacy safety liposomal mitoxantrone (Lipo‐MIT) monotherapy in patients with NK‐cell lymphoma. Lipo‐MIT was administered intravenously at 20 mg/m 2 once every 4 weeks. primary end points were...
Angioimmunoblastic T cell lymphoma (AITL) represents a distinct, aggressive form of peripheral with dismal prognosis. Recent exome sequencing in patients AITL has revealed the frequent coexistence somatic mutations Rho GTPase RhoA (RhoAG17V) and loss-of-function 5-methylcytosine oxidase TET2. Here, we have demonstrated that TET2 loss RhoAG17V expression mature murine cells cooperatively cause abnormal CD4+ proliferation differentiation by perturbing FoxO1 gene expression, phosphorylation,...
Abstract Background Peripheral T cell lymphoma (PTCL) is a rare disease and recent approved drugs for relapsed/refractory (r/r) PTCL provided limited clinical benefit. We conducted this study to evaluate the efficacy safety of geptanolimab (GB226), an anti-PD-1 antibody, in r/r patients. Methods did single-arm, multicenter phase 2 across 41 sites China. Eligible patients with received 3 mg/kg intravenously every weeks until progression or intolerable toxicity. All who at least one dose...
The non-germinal center B-cell like (non-GCB) subtype of diffuse large lymphoma (DLBCL) has poor clinical outcomes. Bruton tyrosine kinase (BTK) inhibitors have established therapeutic activity in malignancies, with modest DLBCL. Zanubrutinib, a potent and selective BTK inhibitor, was evaluated patients relapsed or refractory (R/R) non-GCB BGB-3111-207 study (NCT03145064) multicenter single-arm phase 2 study. Patients received twice-daily oral zanubrutinib, 160 mg, until disease progression...
Glioblastoma multiforme (GBM) is the most common and aggressive primary intracranial malignancy. It characterized by insufficient infiltration of anti-tumor T lymphocytes within tumor microenvironment (TME), rendering it an "immune cold" disease. This immune deficiency results in poor responses to checkpoint blockade (ICB) therapies. Recent studies have demonstrated that bacteria can proliferate tumors activate responses. Therefore, this study, we employed Escherichia coli (E. coli)...
Abstract Background Current proposed KDIGO guidelines suggest systemic corticosteroid therapy to reduce glomerular inflammation in IgA nephropathy (IgAN). While the optimal timing for initiating steroid treatment remains a topic of debate. This study evaluates impact early versus delayed initiation on long-term outcomes IgAN patients. Methods We conducted retrospective 268 patients treated with corticosteroids > 3 months within years kidney biopsy. Patients were categorized into...
Tislelizumab is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody specifically designed to minimize binding Fcγ receptors (FcγR).Here, we present the extended 3-year follow-up of a phase II study tislelizumab in 70 patients with relapsed/refractory classical Hodgkin lymphoma (cHL) who failed or were ineligible for autologous stem transplantation.With median 33.8 months, overall response rate by independent review committee was 87.1%, and complete (CR) 67.1%. Responses...
Relapsed or refractory (r/r) mantle cell lymphoma (MCL) is an aggressive B-cell malignancy with a poor prognosis. Bruton tyrosine kinase (BTK) mediator of receptor signaling and associated the development lymphomas. Patients r/r MCL were enrolled in this phase 1/2 study treated orelabrutinib, novel, highly selective BTK inhibitor. The median number prior regimens was 2 (range, 1-4). age 62 years 37-73 years). Eligible patients received oral orelabrutinib 150 mg once daily (n = 86) 100 twice...